Bacillus licheniformis as a Novel Therapeutic Approach for Huntington’s Disease in Caenorhabditis elegans
- 22 September 2026
- journal article
- research article
- Published by Springer Nature in Indian Journal of Microbiology
- p. 1-20
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Probiotic Bacillus licheniformis MCC2514 and Bifidobacterium breve NCIM 5671 Regulates GATA3 and Foxp3 Expression in the Elevated Disease ConditionProbiotics and Antimicrobial Proteins, 2023
- Gut microbiota-derived metabolites and their importance in neurological disordersMolecular Biology Reports, 2022
- Protective effect of Lactococcus laudensis and Pediococcus parvulus against neuropathy due to amyloid-beta in Caenorhabditis elegansBiomedicine & Pharmacotherapy, 2022
- The Combined Effect of Potential Probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 Towards Anti-inflammatory Activity on HT-29 Cell LinesProbiotics and Antimicrobial Proteins, 2021
- In vitro validation studies for adhesion factor and adhesion efficiency of probiotic Bacillus licheniformis MCC 2514 and Bifidobacterium breve NCIM 5671 on HT-29 cell linesArchives of Microbiology, 2021
- Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegansCell Reports, 2020
- Caenorhabditis elegans: a model to understand host–microbe interactionsCellular and Molecular Life Sciences, 2019
- Diosgenin a phytosterol substitute for cholesterol, prolongs the lifespan and mitigates glucose toxicity via DAF-16/FOXO and GST-4 in Caenorhabditis elegansBiomedicine & Pharmacotherapy, 2017
- Selenite protects Caenorhabditis elegans from oxidative stress via DAF‐16 and TRXR‐1Molecular Nutrition & Food Research, 2013
- Sensory control of dauer larva formation in Caenorhabditis elegansJournal of Comparative Neurology, 1981